SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 29, 2003
|
TRANSGENOMIC, INC. |
||
|
(Exact name of registrant as specified in its charter) |
||
|
|
|
|
|
Delaware |
|
000-30975 |
|
(State of Formation) |
|
(Commission File Number) |
|
|
|
|
|
911789357 |
||
|
(IRS Employer Identification Number) |
||
|
|
|
|
|
12325
Emmet Street |
|
68164 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
|
(402) 452-5400 |
||
|
(Registrants’ telephone number, including area code) |
||
|
|
||
|
Not applicable |
||
|
(Former name or former address, if changed since last report) |
||
Item 5. Other Events and Regulation FD Disclosure.
On May 29, 2003, the Company issued a press release announcing changes in management responsibilities including the appointment of Michael J. Draper as its Chief Financial Officer. The Company is attaching the press release as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated May 29, 2003, announcing changes in management responsibilities including the appointment of Michael J. Draper as Chief Financial Officer of Transgenomic, Inc. (the “Company”).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TRANSGENOMIC, INC. |
||
|
|
|
||
|
|
|
||
|
|
By |
/s/ Michael J. Draper |
|
|
|
|
Michael J. Draper, Chief Financial Officer |
|
|
|
|
||
|
|
|
||
|
May 29, 2003 |
|
||
3